{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:47:08Z","timestamp":1760057228223,"version":"build-2065373602"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:p>We report the <jats:sup>18<\/jats:sup>F-NOTA-pentixather PET\/CT findings of aldosterone-producing adenoma (APA) coincidence with renal cell carcinoma (RCC) in a 36-year-old man. He went to the hospital for persistent hypertension and new limb numbness and weakness. CT showed a nodule in the left adrenal gland, suggestive of an adenoma. <jats:sup>18<\/jats:sup>F-NOTA-pentixather PET\/CT showed the nodule with high NOTA-pentixather uptake. A surprisingly NOTA-pentixather-avid lesion in the right kidney was also noted. Postoperative pathology supported a diagnosis of APA of the left adrenal gland nodule, and the right kidney lesion was RCC.<\/jats:p>","DOI":"10.1097\/rlu.0000000000005945","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T06:00:19Z","timestamp":1747116019000},"page":"1097-1098","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Incidental Detection of Renal Cell Carcinoma on 18F-NOTA-Pentixather PET\/CT in a Patient With Aldosterone-producing Adenoma"],"prefix":"10.1097","volume":"50","author":[{"given":"Lijuan","family":"Feng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,5,8]]},"reference":[{"key":"R1-20251009","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.1007\/s00259-022-05849-y","article-title":"CXCR4-targeted theranostics in oncology","volume":"49","author":"Buck","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R2-20251009","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1007\/s00259-020-04722-0","article-title":"Imaging CXCR4 expression in patients with suspected primary hyperaldosteronism","volume":"47","author":"Ding","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R3-20251009","doi-asserted-by":"crossref","first-page":"e572","DOI":"10.1097\/RLU.0000000000004202","article-title":"Imaging aldosterone-producing adrenocortical carcinoma with 68Ga-pentixafor PET\/CT","volume":"47","author":"Shu","year":"2022","journal-title":"Clin Nucl Med"},{"key":"R4-20251009","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1161\/HYPERTENSIONAHA.117.09975","article-title":"Targeting CXCR4 (CXC chemokine receptor type 4) for molecular imaging of aldosterone-producing adenoma","volume":"71","author":"Heinze","year":"2018","journal-title":"Hypertension"},{"key":"R5-20251009","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/RLU.0000000000002946","article-title":"Intense 68Ga-pentixafor activity in aldosterone-producing adrenal adenomas","volume":"45","author":"Ding","year":"2020","journal-title":"Clin Nucl Med"},{"key":"R6-20251009","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1097\/RLU.0000000000005194","article-title":"Chemokine receptor 4\u2013targeted PET\/CT with 68Ga-pentixather detects more lesions than 68Ga-pentixafor PET\/CT in multiple myeloma","volume":"49","author":"Yang","year":"2024","journal-title":"Clin Nucl Med"},{"key":"R7-20251009","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.2967\/jnumed.120.251447","article-title":"Matched-pair comparison of 68Ga-PSMA-11 and 18F-rhPSMA-7 PET\/CT in patients with primary and biochemical recurrence of prostate cancer: frequency of non\u2013tumor-related uptake and tumor positivity","volume":"62","author":"Kroenke","year":"2021","journal-title":"J Nucl Med"},{"key":"R8-20251009","doi-asserted-by":"crossref","first-page":"85","DOI":"10.18383\/j.tom.2016.00130","article-title":"First 18F-labeled pentixafor-based imaging agent for PET imaging of CXCR4 expression in vivo","volume":"2","author":"Poschenrieder","year":"2016","journal-title":"Tomography"},{"key":"R9-20251009","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s12149-023-01851-y","article-title":"Advances in the molecular imaging of primary aldosteronism","volume":"37","author":"Ren","year":"2023","journal-title":"Ann Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005945","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:04:07Z","timestamp":1760025847000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,8]]},"references-count":9,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005945","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"type":"print","value":"0363-9762"},{"type":"electronic","value":"1536-0229"}],"subject":[],"published":{"date-parts":[[2025,5,8]]},"assertion":[{"value":"2025-03-20","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}